Traduction de «elaprase en naglazyme » (Néerlandais → Français) :

Weesgeneesmiddelen: L01XE10 (Afinitor), L01BB07 (Atriance), B02BD09 (Benefix), L01AB01 (Busilvex), L01XD04 (Gliolan), N03AX17 (Diacomit), A16AA06 (Cystadane), H01AC03 (Increlex), A16AX07 (Kuvan), L01XX23 (Lysodren), L03AX16 (Mozobil), A16AB09 (Elaprase), A16AB08 (Naglazyme), L01BB06 (Evoltra), L01XE05 (Nexavar), B02BX04 (Nplate), V03AC03 (Exjade), B01AC09 (Flolan), C01EB19 (Firazyr), B02BX05 (Revolade), B01AC11 (Ventavis), L04AX04 (Revlimid), L01BC07 (Vidaza), V03AF02 (Savene), C02KX02 (Volibris), L04AA25 (Soliris), N07XX04 (Xyrem), L01XE06 (Sprycel), L01CX01 (Yondelis), L01XE04 (Sutent), L01XE08 (Tasigna), C02KX03 (Thelin), L01XE09 (Torisel), A16AA05 (Carbaglu), A16AX04 (Orfadin), A16AX06 (Zavesca), A16AB07 (Myozyme), G04BE03 (Revatio), L01XX27 (Trisenox), N04BA02 (Duodopa), L01XE01 (Glivec), H01AX01 (Somavert), A16AB05 (Aldurazyme), A16AB04 (Fabrazyme), A16AB03 (Replagal), C02KX01 (Tracleer), L01XX35 (Xagrid)
Médicaments orphelins : L01XE10 (Afinitor), L01BB07 (Atriance), B02BD09 (Benefix), L01AB01 (Busilvex), L01XD04 (Gliolan), N03AX17 (Diacomit), A16AA06 (Cystadane), H01AC03 (Increlex), A16AX07 (Kuvan), L01XX23 (Lysodren), L03AX16 (Mozobil), A16AB09 (Elaprase), A16AB08 (Naglazyme), L01BB06 (Evoltra), L01XE05 (Nexavar), B02BX04 (Nplate), V03AC03 (Exjade), B01AC09 (Flolan), C01EB19 (Firazyr), B02BX05 (Revolade), B01AC11 (Ventavis), L04AX04 (Revlimid), L01BC07 (Vidaza), V03AF02 (Savene), C02KX02 (Volibris), L04AA25 (Soliris), N07XX04 (Xyrem), L01XE06 (Sprycel), L01CX01 (Yondelis), L01XE04 (Sutent), L01XE08 (Tasigna), C02KX03 (Thelin), L01XE09 (Torisel), A16AA05 (Carbaglu), A16AX04 (Orfadin), A16AX06 (Zavesca), A16AB07 (Myozyme), G04BE03 (Revatio), L01XX27 (Trisenox), N04BA02 (Duodopa), L01XE01 (Glivec), H01AX01 (Somavert), A16AB05 (Aldurazyme), A16AB04 (Fabrazyme), A16AB03 (Replagal), C02KX01 (Tracleer), L01XX35 (Xagrid)

In 2008 worden er twee nieuwe farmaceutische specialiteiten ingeschreven nl. Elaprase en Naglazyme.
En 2008, deux nouvelles spécialités pharmaceutiques ont été inscrites, à savoir Elaprase et Naglazyme.